News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.

Marker will initiate a company-sponsored study after an initial trial at Baylor College of Medicine showed positive safety data.

Experts discuss providing supportive care to patients receiving CAR T-cell therapy.

MyoAAV was shown to deliver 25 to 50 times greater gene expression in multiple skeletal muscles compared with natural AAV serotypes.

CT103A, a fully human BCMA-directed CAR T-cell therapy, demonstrated deepening efficacy with an acceptable toxicity profile, according to updated data from the phase 1/2 FUMANBA-1 trial.

No such adverse events have occurred in the lower-dose group.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.

The trial is being launched by the University of Florida Center for Regenerative Medicine in collaboration with RESTEM.

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA will consider RGX-121's BLA in an accelerated approval pathway.

Topline results are expected in the first quarter of 2023.

The professor of neurosurgery at Rush University Medical School discussed the potential of Lineage Cell’s LCTOPC1 cell therapy.

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

The phase 1 clinical trial from Krystal Biotech is expected to begin this year.

Seven participants have been dosed with AGT103-T, an autologous T-cell therapy currently being evaluated in a phase 1 trial.

Elderly or high-risk patients with COVID-19 received 1 of 4 escalating dose levels.

The company voluntarily paused the trial in February 2022 to investigate 2 reported deaths in the trial.

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed remaining research and education needs to support the future of genetic medicines.

Experts shared opinions about the future of gene therapy in sickle cell and other rare diseases.

Review top news and interview highlights from the week ending July 29, 2022.

The announcement follows positive data updates from the ENDEAVOR and SRP-9001-101 studies.

The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.

CYTO-102 is being developed by City of Hope and CytoImmune.

The company announced successful neutrophil and platelet engraftment for the first patient dosed.